Tag: Charitable

Cell Signaling Technology Named a Top Charitable Company in Massachusetts by the Boston Business Journal

For more than 20 years, researchers in pharma, biotech, and academia have trusted CST for its proven biological and technical expertise and our success is directly linked to the global communities where we live and work. “As scientists and citizens, we cannot ignore the important connections we have with each other, our local communities, and the planet as a whole,” said John Letcher, Cell Signaling Technology, Senior Vice President of Global Human Resources. “We are flattered to be recognized by the Boston Business Journal for our contributions within the Commonwealth of Massachusetts.”

CST charitable initiatives are part of a broader Corporate Social Responsibility focus that includes commitments to Our Planet, Science Education, Our Employees, Surrounding Communities, and the Arts.  

At CST we believe in the power of science to help us meet some of the big challenges ahead. Science is our passion, and our mission is to help

Read More

Capillary Biomedical Receives $1.5 Million from Helmsley Charitable Trust for Clinical Trials of New Insulin Infusion Technology

IRVINE, Calif.–(BUSINESS WIRE)–Capillary Biomedical, Inc. (CapBio) has announced that it has received a $1.5 million program-related investment in the form of a loan from The Leona M. and Harry B. Helmsley Charitable Trust (Helmsley). The use of funds includes clinical studies of CapBio’s novel SteadiFlowtm technology to evaluate the potential for extended-wear of insulin infusion sets by people with Type 1 diabetes for 7 days and beyond.

CapBio’s SteadiSettm infusion set, powered by its SteadiFlow technology platform, is designed to increase the wear time of insulin infusion sets by addressing the common causes of infusion site failure. Infusion sets are a key component of recently introduced automated insulin delivery (AID) systems that use continuous glucose monitoring (CGM) sensors to guide insulin pump therapy. Sets are designed to be changed every two to three days, but sites often fail sooner. Infusion site failures can lead to diabetic

Read More